Related Experiment Video

Updated: Jun 12, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Complement receptor 1 gene polymorphism and cardiovascular disease in dialyzed end-stage renal disease patients

Monika Buraczynska1, Piotr Ksiazek, Piotr Wacinski

  • 1Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland. monika.buraczynska@am.lublin.pl

Human Immunology
|June 12, 2010
PubMed

Insights

Genetic variations in the complement receptor 1 (CR1) gene are linked to cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD). The CR1 C5507G polymorphism, specifically the GG genotype, is an independent risk factor for CVD in this population.

Area of Science:

  • Genetics
  • Cardiology
  • Nephrology

Background:

  • Inflammation is a key factor in cardiovascular disease (CVD) development.
  • The complement system, part of innate and acquired immunity, is implicated in inflammatory processes.
  • End-stage renal disease (ESRD) patients exhibit a higher prevalence of CVD.

Purpose of the Study:

  • To investigate the association between complement receptor 1 (CR1) gene polymorphisms and CVD in patients with ESRD.
  • To determine if CR1 gene variations act as risk factors for CVD in the ESRD population.

Main Methods:

  • Genotyping of CR1 gene polymorphisms (C5507G) in 1200 ESRD patients, 360 type 2 diabetes patients, and 924 healthy controls.
  • Statistical analysis including odds ratios (OR), confidence intervals (CI), and multivariate logistic regression.
  • Comparison of genotype and allele frequencies between patient groups and controls.

Main Results:

  • The GG genotype of the CR1 C5507G polymorphism was significantly more frequent in ESRD patients with CVD compared to those without CVD and controls (ORs 3.44-5.46).
  • This GG genotype was present in 62% of ESRD patients with a history of myocardial infarction.
  • The G allele of C5507G was also more frequent in ESRD patients with CVD (ORs 1.97-2.24) and identified as an independent risk factor (p < 0.001).

Conclusions:

  • The CR1 gene C5507G polymorphism is strongly associated with CVD in ESRD patients.
  • The GG genotype and G allele carrier status represent significant risk factors for developing CVD in this patient cohort.
  • These findings highlight the role of the complement system in CVD pathogenesis within the context of ESRD.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...